Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents.

Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM.

Arthritis Rheum. 2003 Feb;48(2):319-24.

2.

TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis.

Tobin AM, Kirby B.

BioDrugs. 2005;19(1):47-57. Review.

PMID:
15691217
3.

TNFalpha as therapeutic target: new drugs, more applications.

Reimold AM.

Curr Drug Targets Inflamm Allergy. 2002 Dec;1(4):377-92. Review.

PMID:
14561184
4.

Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis.

Gilaberte Y, Coscojuela C, Vázquez C, Roselló R, Vera J.

Br J Dermatol. 2007 Feb;156(2):368-71. Review.

PMID:
17223880
5.

Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience.

Braun J, Sieper J, Breban M, Collantes-Estevez E, Davis J, Inman R, Marzo-Ortega H, Mielants H.

Ann Rheum Dis. 2002 Dec;61 Suppl 3:iii51-60. Review.

6.

[TNFalpha inhibitors for the treatment of rheumatoid arthritis].

Sany J, Kaiser MJ.

Ann Med Interne (Paris). 2002 Feb;153(1):34-40. Review. French.

PMID:
11994688
7.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
8.

Safety of biologic therapies--an update.

Keystone EC.

J Rheumatol Suppl. 2005 Mar;74:8-12. Review.

PMID:
15742458
9.

What are the risks of biologic therapy in rheumatoid arthritis? An update on safety.

Weisman MH.

J Rheumatol Suppl. 2002 Sep;65:33-8. Review.

PMID:
12236621
10.

Optic neuritis occurring with anti-tumour necrosis factor alpha therapy.

Simsek I, Erdem H, Pay S, Sobaci G, Dinc A.

Ann Rheum Dis. 2007 Sep;66(9):1255-8. Epub 2007 Apr 24. Review.

11.

How do the biologics fit into the current DMARD armamentarium?

Kalden JR.

J Rheumatol Suppl. 2001 Jun;62:27-35. Review.

PMID:
11409155
12.

Serious infections associated with anticytokine therapies in the rheumatic diseases.

Giles JT, Bathon JM.

J Intensive Care Med. 2004 Nov-Dec;19(6):320-34. Review.

PMID:
15523118
13.

The benefit/risk profile of TNF-blocking agents: findings of a consensus panel.

Hochberg MC, Lebwohl MG, Plevy SE, Hobbs KF, Yocum DE.

Semin Arthritis Rheum. 2005 Jun;34(6):819-36. Review.

PMID:
15942917
14.

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Hyrich KL, Silman AJ, Watson KD, Symmons DP.

Ann Rheum Dis. 2004 Dec;63(12):1538-43. Epub 2004 Jul 8. Review.

15.

Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections?

Kelesidis T, Salhotra A, Fleisher J, Uslan DZ.

J Infect. 2010 May;60(5):386-96. doi: 10.1016/j.jinf.2010.02.009. Epub 2010 Feb 20. Review.

PMID:
20176052
16.

Infectious complications with anti-TNFalpha therapy in rheumatic diseases: a review.

Toussirot E, Streit G, Wendling D.

Recent Pat Inflamm Allergy Drug Discov. 2007 Feb;1(1):39-47. Review.

PMID:
19075965
17.

Sarcoidosis appearing during anti-tumor necrosis factor alpha therapy: a new "class effect" paradoxical phenomenon. Two case reports and literature review.

Massara A, Cavazzini L, La Corte R, Trotta F.

Semin Arthritis Rheum. 2010 Feb;39(4):313-9. doi: 10.1016/j.semarthrit.2008.11.003. Epub 2009 Jan 15. Review.

PMID:
19147181
18.

Nonserious infections: should there be cause for serious concerns?

Dao KH, Herbert M, Habal N, Cush JJ.

Rheum Dis Clin North Am. 2012 Nov;38(4):707-25. doi: 10.1016/j.rdc.2012.08.016. Review.

PMID:
23137578
19.

[Efficacy and adverse reactions of the TNFalpha inhibitor infliximab in rheumatoid arthritis].

Imagama T, Taguchi T.

Nihon Rinsho. 2013 Jul;71(7):1209-13. Review. Japanese.

PMID:
23961668
20.

Safety of anti-TNFalpha therapy in children with juvenile idiopathic arthritis.

Dekker L, Armbrust W, Rademaker CM, Prakken B, Kuis W, Wulffraat NM.

Clin Exp Rheumatol. 2004 Mar-Apr;22(2):252-8. Review.

PMID:
15083897

Supplemental Content

Support Center